Tango Therapeutics (TNGX) Stock Forecast & Price Target

Compare

436 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TNGX Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Tango

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TNGX Stock 12 Month Forecast

Average Price Target

$13.71

▲(5.38% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Tango Therapeutics in the last 3 months. The average price target is $13.71 with a high forecast of $15.00 and a low forecast of $12.00. The average price target represents a 5.38% change from the last price of $13.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.332307692307692,9.804615384615385,10.276923076923076,10.749230769230769,11.221538461538461,11.693846153846154,12.166153846153847,12.638461538461538,13.11076923076923,13.583076923076923,14.055384615384614,14.527692307692309,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.233076923076922,9.606153846153846,9.97923076923077,10.352307692307692,10.725384615384616,11.098461538461539,11.471538461538461,11.844615384615384,12.217692307692309,12.590769230769231,12.963846153846156,13.336923076923078,{"y":13.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.10153846153846,9.343076923076923,9.584615384615384,9.826153846153845,10.067692307692308,10.30923076923077,10.55076923076923,10.792307692307691,11.033846153846154,11.275384615384615,11.516923076923078,11.758461538461539,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$15.00

Average Price Target$13.71

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kelsey Goodwin

Piper Sandler

$11→$14

Buy

7.61%

Upside

Reiterated

01/16/26

Tango Therapeutics price target raised to $14 from $11 at Piper SandlerTango Therapeutics price target raised to $14 from $11 at Piper Sandler

Laura Prendergast

Stifel Nicolaus

$15

Buy

15.30%

Upside

Reiterated

01/12/26

Yuan Zhi

B. Riley Securities

$8→$14

Buy

7.61%

Upside

Reiterated

11/17/25

B. Riley Securities Remains a Buy on Tango Therapeutics (TNGX)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

Hold

―

Initiated

11/17/25

Tango Therapeutics initiated with a Peer Perform at Wolfe ResearchTango Therapeutics initiated with a Peer Perform at Wolfe Research

Robert Burns

H.C. Wainwright

$13

Buy

-0.08%

Downside

Reiterated

11/05/25

Tango Therapeutics (TNGX) Gets a Buy from H.C. Wainwright

Peter Lawson

Barclays

$13

Buy

-0.08%

Downside

Reiterated

11/04/25

Barclays Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

Michael Schmidt

Guggenheim

$12

Buy

-7.76%

Downside

Reiterated

10/23/25

Tango Therapeutics price target raised to $12 from $10 at GuggenheimTango Therapeutics price target raised to $12 from $10 at Guggenheim

Robert Driscoll

Wedbush

$15

Buy

15.30%

Upside

Reiterated

10/23/25

Andrew Berens

Leerink Partners

$10

Buy

-23.14%

Downside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kelsey Goodwin

Piper Sandler

$11→$14

Buy

7.61%

Upside

Reiterated

01/16/26

Tango Therapeutics price target raised to $14 from $11 at Piper SandlerTango Therapeutics price target raised to $14 from $11 at Piper Sandler

Laura Prendergast

Stifel Nicolaus

$15

Buy

15.30%

Upside

Reiterated

01/12/26

Yuan Zhi

B. Riley Securities

$8→$14

Buy

7.61%

Upside

Reiterated

11/17/25

B. Riley Securities Remains a Buy on Tango Therapeutics (TNGX)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

Hold

―

Initiated

11/17/25

Tango Therapeutics initiated with a Peer Perform at Wolfe ResearchTango Therapeutics initiated with a Peer Perform at Wolfe Research

Robert Burns

H.C. Wainwright

$13

Buy

-0.08%

Downside

Reiterated

11/05/25

Tango Therapeutics (TNGX) Gets a Buy from H.C. Wainwright

Peter Lawson

Barclays

$13

Buy

-0.08%

Downside

Reiterated

11/04/25

Barclays Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

Michael Schmidt

Guggenheim

$12

Buy

-7.76%

Downside

Reiterated

10/23/25

Tango Therapeutics price target raised to $12 from $10 at GuggenheimTango Therapeutics price target raised to $12 from $10 at Guggenheim

Robert Driscoll

Wedbush

$15

Buy

15.30%

Upside

Reiterated

10/23/25

Andrew Berens

Leerink Partners

$10

Buy

-23.14%

Downside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tango Therapeutics

3 Months

xxx

Success Rate

11/16 ratings generated profit

Average Return

+54.97%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +54.97% per trade.

1 Year

Peter LawsonBarclays

Success Rate

11/16 ratings generated profit

Average Return

+133.09%

reiterated a buy rating 3 months ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +133.09% per trade.

2 Years

xxx

Success Rate

14/16 ratings generated profit

Average Return

+140.28%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +140.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TNGX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TNGX has received 7 Buy Ratings, 27 Hold Ratings, and 0 Sell Ratings. TNGX average Analyst price target in the past 3 months is 13.71.

Each month's total comprises the sum of three months' worth of ratings.

TNGX Financial Forecast

TNGX Earnings Forecast

Next quarter’s earnings estimate for TNGX is -$0.32 with a range of -$0.52 to -$0.24. The previous quarter’s EPS was $0.14. TNGX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TNGX has Performed in-line its overall industry.

TNGX Sales Forecast

Next quarter’s sales forecast for TNGX is $500.00K with a range of $0.00 to $5.00M. The previous quarter’s sales results were $53.81M. TNGX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TNGX has Performed in-line its overall industry.

TNGX Stock Forecast FAQ

What is TNGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Tango Therapeutics’s 12-month average price target is 13.71.

What is TNGX’s upside potential, based on the analysts’ average price target?

Tango Therapeutics has 5.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TNGX a Buy, Sell or Hold?

Tango Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Tango Therapeutics’s price target?

The average price target for Tango Therapeutics is 13.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $12.00. The average price target represents 5.38% Increase from the current price of $13.01.

What do analysts say about Tango Therapeutics?

Tango Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of TNGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Tango Therapeutics (TNGX) Stock Forecast & Price Target

TNGX Analyst Ratings

TNGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tango Therapeutics

TNGX Analyst Recommendation Trends

TNGX Financial Forecast

TNGX Earnings Forecast

TNGX Sales Forecast

TNGX Stock Forecast FAQ

Detailed List of Analyst Forecasts